Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
KIN's Cash-to-Debt is ranked higher than
71% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. KIN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
KIN' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
KIN's Interest Coverage is ranked higher than
65% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. KIN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
KIN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: 21.80
WACC vs ROIC
10.93%
-763.75%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -33.59
KIN's ROE % is ranked higher than
54% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. KIN: -33.59 )
Ranked among companies with meaningful ROE % only.
KIN' s ROE % Range Over the Past 10 Years
Min: -33.59  Med: -32.19 Max: -13.34
Current: -33.59
-33.59
-13.34
ROA % -32.29
KIN's ROA % is ranked higher than
51% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. KIN: -32.29 )
Ranked among companies with meaningful ROA % only.
KIN' s ROA % Range Over the Past 10 Years
Min: -32.42  Med: -29.89 Max: -12.68
Current: -32.29
-32.42
-12.68
ROC (Joel Greenblatt) % -1279.95
KIN's ROC (Joel Greenblatt) % is ranked lower than
64% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. KIN: -1279.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
KIN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -70316.67  Med: -8371.98 Max: -1238.75
Current: -1279.95
-70316.67
-1238.75
GuruFocus has detected 2 Warning Signs with Kindred Biosciences Inc $KIN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» KIN's 10-Y Financials

Financials (Next Earnings Date: 2017-06-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

KIN Guru Trades in Q1 2016

Chuck Royce 148,000 sh (+64.44%)
John Rogers 3,587,561 sh (+43.61%)
Seth Klarman 3,013,848 sh (unchged)
Jim Simons 217,900 sh (-18.05%)
» More
Q2 2016

KIN Guru Trades in Q2 2016

Jim Simons 302,700 sh (+38.92%)
John Rogers 3,695,576 sh (+3.01%)
Seth Klarman 3,013,848 sh (unchged)
Chuck Royce 148,000 sh (unchged)
» More
Q3 2016

KIN Guru Trades in Q3 2016

Jim Simons 331,600 sh (+9.55%)
John Rogers 3,835,163 sh (+3.78%)
Chuck Royce 148,000 sh (unchged)
Seth Klarman 3,011,584 sh (-0.08%)
» More
Q4 2016

KIN Guru Trades in Q4 2016

Jim Simons 351,600 sh (+6.03%)
John Rogers 3,940,859 sh (+2.76%)
Chuck Royce 148,000 sh (unchged)
Seth Klarman Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KIN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541940    SIC: 742
Compare:AMEX:PLX, AMEX:AST, NAS:GLYC, NAS:VTL, NAS:ARWR, NAS:SBBP, NAS:REPH, NAS:XENE, NAS:VBLT, AMEX:PFNX, OTCPK:HSDT, OTCPK:PAIOF, NAS:CLSD, OTCPK:INNMF, NAS:NYMX, OTCPK:PHGUF, NAS:ALBO, NAS:QURE, NYSE:KDMN, NAS:GNCA » details
Traded in other countries:17K.Germany,
Kindred Biosciences Inc is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. The Company's product candidates are SentiKind, KIND-010 and KIND-012.

Kindred Biosciences Inc is a development stage biopharmaceutical company developing pet care products. The company identifies compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. Kindred Biosciences has a pipeline of novel drugs and biologics in development across various therapeutic classes. Its pipeline products include Mirataz, Zimeta, KIND-014, KIND-015, epoCat, Anti-Interleukin anibodeis, Anti-CD20, Anti-IgE, Anti-VEGF, Anti-TNF, and Checkpoint Inhibitors.

Top Ranked Articles about Kindred Biosciences Inc

John Rogers Invests in Bristow Group, Kindred Biosciences Guru boosts Bristow stake by 24%
John Rogers (Trades, Portfolio), founder of Ariel Investment LLC, added to two stakes in his portfolio – Bristow Group Inc. (NYSE:BRS) and Kindred Biosciences Inc. (NASDAQ:KIN) – on March 31. Read more...

Ratios

vs
industry
vs
history
PB Ratio 2.45
KIN's PB Ratio is ranked higher than
68% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. KIN: 2.45 )
Ranked among companies with meaningful PB Ratio only.
KIN' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.48
Current: 2.45
0
2.48
Current Ratio 15.01
KIN's Current Ratio is ranked higher than
90% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. KIN: 15.01 )
Ranked among companies with meaningful Current Ratio only.
KIN' s Current Ratio Range Over the Past 10 Years
Min: 13.4  Med: 22.99 Max: 35.59
Current: 15.01
13.4
35.59
Quick Ratio 15.01
KIN's Quick Ratio is ranked higher than
90% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. KIN: 15.01 )
Ranked among companies with meaningful Quick Ratio only.
KIN' s Quick Ratio Range Over the Past 10 Years
Min: 13.4  Med: 22.99 Max: 35.59
Current: 15.01
13.4
35.59

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.72
KIN's Price-to-Net-Cash is ranked higher than
79% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. KIN: 2.72 )
Ranked among companies with meaningful Price-to-Net-Cash only.
KIN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.97  Med: 1.55 Max: 2.73
Current: 2.72
0.97
2.73
Price-to-Net-Current-Asset-Value 2.65
KIN's Price-to-Net-Current-Asset-Value is ranked higher than
79% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. KIN: 2.65 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
KIN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.96  Med: 1.53 Max: 2.66
Current: 2.65
0.96
2.66
Price-to-Tangible-Book 2.48
KIN's Price-to-Tangible-Book is ranked higher than
73% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. KIN: 2.48 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
KIN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.88  Med: 1.48 Max: 2.66
Current: 2.48
0.88
2.66
Earnings Yield (Greenblatt) % -22.62
KIN's Earnings Yield (Greenblatt) % is ranked lower than
68% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. KIN: -22.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
KIN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2000  Med: 0 Max: 0
Current: -22.62
-2000
0

More Statistics

EPS (TTM) $ -1.14
Beta1.11
Short Percentage of Float0.69%
52-Week Range $3.12 - 7.45
Shares Outstanding (Mil)22.07

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 9 56
EPS ($) -1.60 -0.75
EPS without NRI ($) -1.60 -0.75
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for KIN

Headlines

Articles On GuruFocus.com
10 Stocks John Rogers Keeps Buying Sep 27 2016 
John Rogers Invests in Bristow Group, Kindred Biosciences Apr 08 2016 
Guru John Rogers Raises Stake in Helping Animals Dec 16 2015 
Seth Klarman Nearly Doubles Stake in Atara Biotherapeutics Apr 15 2015 
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
Seth Klarman Buys New Stock Kindred Biosciences, Cut Stake in Enzon Jan 10 2014 

More From Other Websites
Kindred Biosciences to Present at 2017 Jefferies Animal Health Summit Mar 16 2017
KINDRED BIOSCIENCES, INC. Financials Mar 08 2017
Kindred Biosciences Announces Global Sponsorship of International Society of Equine Locomotor... Mar 07 2017
Kindred Bio reports 4Q loss Mar 01 2017
Kindred Bio reports 4Q loss Mar 01 2017
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition Mar 01 2017
Kindred Biosciences Announces Fourth Quarter and Year-End 2016 Financial Results Mar 01 2017
Q4 2016 Kindred Biosciences Inc Earnings Release - After Market Close Mar 01 2017
Kindred Biosciences to Announce Fourth Quarter and Year-End 2016 Financial Results Feb 21 2017
Kindred Biosciences Receives Early Approval of Effectiveness Technical Section from FDA for... Feb 06 2017
Insider Buying Slows as Trump Inauguration Takes Center Stage: Kindred Biosciences, Mirati... Jan 22 2017
These Insiders Are Still Finding Some Good Value in the Stock Market Jan 19 2017
Kindred Biosciences (KIN) Looks Good: Stock Jumps 9.5% Jan 16 2017
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 06 2017
The 2017 Gad Value Investment Fund, Part 2 Dec 28 2016
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Dec 19 2016
Digirad Corporation (DRAD): Are Hedge Funds Right About This Stock? Dec 14 2016
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Dec 07 2016
Kindred Biosciences, Inc. :KIN-US: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016 Dec 05 2016
Kindred Biosciences to Present Zimeta Pivotal Data at the 62nd Annual American Association of Equine... Nov 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)